Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors

Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadkowiec, Karolina N., Stawinski, Peter M., Proenza, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813547/
https://www.ncbi.nlm.nih.gov/pubmed/33490300
http://dx.doi.org/10.14309/crj.0000000000000530
_version_ 1783637872849453056
author Dziadkowiec, Karolina N.
Stawinski, Peter M.
Proenza, Jose
author_facet Dziadkowiec, Karolina N.
Stawinski, Peter M.
Proenza, Jose
author_sort Dziadkowiec, Karolina N.
collection PubMed
description Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tract infections among others. We present a case of severe epigastric abdominal pain consistent with acute pancreatitis in the setting of empagliflozin use, suggesting a possible drug-induced acute pancreatitis.
format Online
Article
Text
id pubmed-7813547
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-78135472021-01-21 Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors Dziadkowiec, Karolina N. Stawinski, Peter M. Proenza, Jose ACG Case Rep J Case Report Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tract infections among others. We present a case of severe epigastric abdominal pain consistent with acute pancreatitis in the setting of empagliflozin use, suggesting a possible drug-induced acute pancreatitis. Wolters Kluwer 2021-01-19 /pmc/articles/PMC7813547/ /pubmed/33490300 http://dx.doi.org/10.14309/crj.0000000000000530 Text en © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Dziadkowiec, Karolina N.
Stawinski, Peter M.
Proenza, Jose
Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
title Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
title_full Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
title_fullStr Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
title_full_unstemmed Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
title_short Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
title_sort empagliflozin-associated pancreatitis: a consideration for sglt2 inhibitors
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813547/
https://www.ncbi.nlm.nih.gov/pubmed/33490300
http://dx.doi.org/10.14309/crj.0000000000000530
work_keys_str_mv AT dziadkowieckarolinan empagliflozinassociatedpancreatitisaconsiderationforsglt2inhibitors
AT stawinskipeterm empagliflozinassociatedpancreatitisaconsiderationforsglt2inhibitors
AT proenzajose empagliflozinassociatedpancreatitisaconsiderationforsglt2inhibitors

Ejemplares similares